혈액내과5 편

영향력 2

Economic burden associated with switching from frontline pegaspargase or calaspargase pegol to second-line recombinant

발표일: 2026-12-01

Journal of medical economics

MediLens 수록일: 2026-05-23

This retrospective study assessed the costs and healthcare resource utilization associated with switching from frontline pegaspargase/cal-aspargase pegol to second-line recombinant asparaginase in pediatric and AYA patients with acute lymphoblastic leukemia (ALL). A total of 154 patients were ide...

PubMed에서 읽기

영향력 2

Hungry bone syndrome-like state following denosumab in a patient with multiple myeloma.

발표일: 2026-07-01

JCEM case reports

MediLens 수록일: 2026-05-23

This case study presents a 76-year-old man with newly diagnosed multiple myeloma who experienced severe, prolonged hypocalcemia following denosumab treatment. The patient had elevated creatinine and calcium levels prior to treatment, and developed significant mineral imbalances despite aggressive...

PubMed에서 읽기

영향력 3

Hypophosphatemia as a Marker for Immune Effector Cell-Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor T Cell Recipients.

발표일: 2026-05-22

Hematology/oncology and stem cell therapy

MediLens 수록일: 2026-05-23

Hypophosphatemia is prevalent in patients undergoing CAR-T therapy, occurring in 71.5% of recipients. The condition is linked to an increased risk of immune effector cell-associated neurotoxicity syndrome (ICANS), with a hazard ratio of 2.87. Notably, hypophosphatemia typically precedes ICANS by ...

PubMed에서 읽기

영향력 2

Haploidentical donor versus double-unit cord blood transplantation in hematologic malignancies: comparative survival and graft-versus-host disease outcomes from a decade of real-world experience.

발표일: 2026-05-22

BMC cancer

MediLens 수록일: 2026-05-23

This study compares haploidentical donor (HID) and double-unit umbilical cord blood (DUCB) transplantation in 97 patients with hematologic malignancies. HID recipients had faster neutrophil and platelet recovery and lower rates of grade II-IV acute GVHD compared to DUCB recipients. However, overa...

PubMed에서 읽기

영향력 2

The Two-Step Allogeneic Stem Cell Transplant Is Associated with Excellent Engraftment, Improved Survival and Low Nonrelapse Mortality in Patients with Myelofibrosis.

발표일: 2026-05-22

Hematology/oncology and stem cell therapy

MediLens 수록일: 2026-05-23

This study evaluates the outcomes of 32 myelofibrosis patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) using a two-step transplant approach. The approach resulted in favorable 1-year and 5-year overall survival rates of 83% and 68%, respectively, and reduced nonrel...

PubMed에서 읽기

의학 연구 트렌드

혈액내과5 편

Economic burden associated with switching from frontline pegaspargase or calaspargase pegol to second-line recombinant

Hungry bone syndrome-like state following denosumab in a patient with multiple myeloma.

Hypophosphatemia as a Marker for Immune Effector Cell-Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor T Cell Recipients.

Haploidentical donor versus double-unit cord blood transplantation in hematologic malignancies: comparative survival and graft-versus-host disease outcomes from a decade of real-world experience.

The Two-Step Allogeneic Stem Cell Transplant Is Associated with Excellent Engraftment, Improved Survival and Low Nonrelapse Mortality in Patients with Myelofibrosis.

매일 맞춤형 요약을 받아보세요